—Partnership combines Gilead’s proven track record and mission to develop transformative therapeutics targeting serious viral diseases, with Assembly Bio’s expertise and focus on antiviral R&D to advance differentiated treatments for herpesviruses, HBV, HDV and beyond—
—Collaboration includes Assembly Bio’s current and future pipeline candidates and incorporates two Gilead herpesvirus programs—
—Assembly Bio to receive $100 million upfront payment, including equity investment, plus potential for future regulatory, commercial, opt-in and collaboration extension payments—
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.